Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

1
Anti-hypertensive Therapeutics in Asia-Pacific
Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak
Pipeline
Single User License - 4995 Site User License
- 9990 Corporate User License -
14985 Publication Date - Jul 2015 Pages -
82 To know more details, email to
debora_at_reportstack.com
2
Summary

• Hypertension is a chronic medical condition
  characterized by elevated blood pressure in the
  arteries. It affected an estimated 517 million
  people in 2014, a figure that will grow at a
  Compound Annual Growth Rate (CAGR) of 1.2 to 561
  million in 2021 in the four Asia-Pacific (APAC)
  regions of China, India, Australia, and Japan.
  This high prevalence is a substantial contributor
  to healthcare costs and a major cause of
  morbidity. Despite this, awareness of
  hypertension is low among physicians, patients,
  and the public alike, leading to poor blood
  pressure control.

3
Scope

• Hypertension prevalence is a prominent
  contributor to market size in the assessed
  countries. The market is mostly dominated by
  generics, and there are only a few patented
  products.
• Will generics continue to dominate treatment?
• How do the elderly populations and their
  associated risk factors affect prevalence?
• The current anti-hypertensive therapeutics
  pipeline is weak, comprising 124 molecules in
  various stages of development, dominated by small
  molecules.
• Will the upcoming molecules change the treatment
  paradigm in the near future?
• How will the weak pipeline affect the market?
• Analysis of clinical trials since 2006 identified
  that anti-hypertensive products have a high rate
  of attrition.

4
Key Benefits

• Understand the clinical context of hypertension
  by considering symptoms, etiology,
  pathophysiology, co-morbidities and
  complications, epidemiology, diagnosis, and
  treatment options.
• Identify the therapeutic strategies, products,
  and companies that dominate the current marketed
  products landscape, and recognize gaps.
• Appreciate key anti-hypertensive pipeline trends
  in molecule type, administration route, mechanism
  of action, and novelty.
• Consider market opportunities and potential risks
  by examining trends in anti-hypertensive clinical
  trial size, duration, and failure rate by stage
  of development, molecule type, and mechanism of
  action.

5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com